PHF7 Inhibitors
Chemical inhibitors of PHF7 operate through various mechanistic pathways to modulate the activity of the protein. LY294002 and Wortmannin are both inhibitors of phosphoinositide 3-kinases (PI3Ks), which play a pivotal role in cellular signaling. By inhibiting PI3Ks, these chemicals can alter the downstream AKT signaling pathway, which may be involved in the regulation of PHF7 activity. Rapamycin, targeting the mTOR pathway, can also affect PHF7 function, as mTOR is central to cell growth and metabolism, pathways that PHF7 might be a part of. Bortezomib and MG132 are proteasome inhibitors that prevent the degradation of ubiquitinated proteins, leading to an accumulation that can disrupt various signaling pathways and potentially affect PHF7 function if it requires regulated protein turnover.
PD98059 and U0126 both target MEK, which is upstream of extracellular signal-regulated kinases (ERKs). These inhibitors prevent the activation of ERK, which can alter the phosphorylation state of proteins and may affect PHF7 activity if it is regulated via ERK signaling. SB203580 and SP600125 inhibit p38 MAP kinase and c-Jun N-terminal kinase (JNK), respectively, which could modify the phosphorylation state of proteins and alter transcription factor activation that are relevant to the activity of PHF7. Dasatinib, an inhibitor of Src family kinases, and Imatinib, which targets BCR-ABL, c-Kit, and PDGFR kinases, can modulate various signaling pathways that may have a role in the regulation of PHF7. Lastly, Roscovitine, a cyclin-dependent kinase (CDK) inhibitor, can affect the activity of PHF7 by potentially altering cell cycle-dependent phosphorylation events.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). Since PI3K signaling is crucial for many cellular processes, including cell growth and survival pathways that PHF7 might be involved in, inhibition of PI3K by LY294002 could reduce the activity of PHF7 by limiting its cellular context for action. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERKs). By inhibiting MEK, PD98059 prevents the activation of ERK, potentially reducing the phosphorylation state of proteins and thereby the activity of proteins like PHF7 that are regulated via ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of the p38 MAPK pathway could alter the phosphorylation state of proteins and potentially affect the function of PHF7 if it is regulated through stress or cytokine-induced signaling pathways that involve p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 can alter transcription factor activation and cellular stress responses, which could reduce the activity of PHF7 if it functions in a pathway requiring JNK signaling for proper activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Accumulation of these proteins could disrupt various signaling pathways, potentially leading to a reduction in PHF7 activity if it requires regulated protein degradation for its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor similar to Bortezomib. It prevents the degradation of polyubiquitinated proteins, which could lead to the disturbance in the regulatory pathways where PHF7 activity is modulated through controlled protein turnover. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that can inhibit Src family kinases. Since Src kinases are involved in numerous signaling pathways, their inhibition by Dasatinib could lead to a reduction in PHF7 activity if PHF7 is regulated by Src kinase-mediated phosphorylation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which, like PD98059, prevents the activation of ERK. Inhibition of this pathway by U0126 could lead to decreased activity of PHF7 if it relies on MEK/ERK signaling for its regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, which plays a central role in cell growth and metabolism. Inhibiting mTOR with Rapamycin could decrease the activity of PHF7 if PHF7 function depends on mTOR-regulated pathways for its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, similar to LY294002, Wortmannin could lead to a decrease in PHF7 activity by affecting the PI3K/AKT signaling pathway, which might regulate PHF7 function. | ||||||